questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the Institute of Cancer Research's report entitled Cost-utility analysis of adding abiraterone acetate plus prednisone/
answerText: Abiraterone has a United Kingdom marketing authorisation for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated, and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-contain...
heading: Prostate Cancer: Hormone Treatments